{"transactions":[{"id":908341,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":310000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":7.87,"expiration_date":"2030-03-06","underlying":"Ordinary Shares","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908340,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":13.57,"expiration_date":"2034-02-20","underlying":"Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908339,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.69,"expiration_date":"2032-08-04","underlying":"Ordinary Shares","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908338,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":310000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":8.2,"expiration_date":"2031-12-07","underlying":"Ordinary Shares","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908337,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":6.79,"expiration_date":"2030-12-08","underlying":"Ordinary Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908336,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.71,"expiration_date":"2029-05-30","underlying":"Ordinary Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908335,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.85,"expiration_date":"2029-03-07","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908334,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":7.06,"expiration_date":"2028-03-22","underlying":"Ordinary Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908333,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":8.95,"expiration_date":"2027-12-12","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908332,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":10.4,"expiration_date":"2026-12-14","underlying":"Ordinary Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908331,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"price":21,"value":210000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc (\"Issuer\"), nominal value $0.01 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the \"Transaction Agreement\") by and between Issuer and Alkermes plc (\"Parent\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Parent acquired Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $21.00 in cash (the \"Cash Consideration\") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a \"CVR\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc (\"Issuer\"), nominal value $0.01 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the \"Transaction Agreement\") by and between Issuer and Alkermes plc (\"Parent\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Parent acquired Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $21.00 in cash (the \"Cash Consideration\") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a \"CVR\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":908330,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-12T17:32:06.000Z","date":"2026-02-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":211105,"price":21,"value":4433205.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc (\"Issuer\"), nominal value $0.01 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the \"Transaction Agreement\") by and between Issuer and Alkermes plc (\"Parent\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Parent acquired Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $21.00 in cash (the \"Cash Consideration\") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a \"CVR\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a \"Restricted Stock Award\"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc (\"Issuer\"), nominal value $0.01 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the \"Transaction Agreement\") by and between Issuer and Alkermes plc (\"Parent\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Parent acquired Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $21.00 in cash (the \"Cash Consideration\") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a \"CVR\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-014441","document":"tm266121-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465926014441/tm266121-2_4seq1.xml","form_type":"4"}},{"id":1218248,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T16:06:44.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest, if at all, in four equal increments if the volume-weighted average price of the Issuer's Ordinary Shares during any 30 calendar day period exceeds $11, $14, $17 and $19.09, respectively."}],"balance_after":310000,"derivative":{"exercise_price":7.87,"expiration_date":"2030-03-06","underlying":"Ordinary Shares","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001104659-25-021732","document":"tm258534-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925021732/tm258534-1_4seq1.xml","form_type":"4"}},{"id":1218247,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-07T16:06:44.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of a restricted share award. The restricted share award shall vest in equal annual installments on each of the first four anniversaries following the 3/5/2025 grant date."}],"balance_after":211100,"source":{"system":"sec-edgar","filing":"0001104659-25-021732","document":"tm258534-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465925021732/tm258534-1_4seq1.xml","form_type":"4"}},{"id":1337918,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-12-10T18:14:56.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":402,"price":9.82,"value":3947.64,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-24-127300","document":"tm2430692-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924127300/tm2430692-1_4seq1.xml","form_type":"4"}},{"id":1337917,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-12-10T18:14:56.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":9598,"price":9.977,"value":95759.246,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.925 to $10.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary."}],"balance_after":9598,"source":{"system":"sec-edgar","filing":"0001104659-24-127300","document":"tm2430692-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924127300/tm2430692-1_4seq1.xml","form_type":"4"}},{"id":1604423,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T06:24:03.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options become exercisable as to 150,000 ADSs on each of the first four anniversaries after the 2/20/2024 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":600000,"derivative":{"exercise_price":13.57,"expiration_date":"2034-02-20","underlying":"ADSs","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001104659-24-030219","document":"tm247077-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924030219/tm247077-5_4seq1.xml","form_type":"4"}},{"id":1811147,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"ADSs","published_at":"2023-08-10T18:45:18.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":13.1997,"value":131997.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.86 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":159100,"source":{"system":"sec-edgar","filing":"0001104659-23-089935","document":"tm2323474-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923089935/tm2323474-1_4seq1.xml","form_type":"4"}},{"id":1868027,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T21:29:37.000Z","date":"2023-06-05","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2022, the Reporting Person was granted an option to purchase 350,000 ADSs, for which vesting was subject to the satisfaction of certain performance criteria. The performance criteria were met on June 5, 2023 (the \"First Vesting Date\"), resulting in the vesting of 50% of the ADSs underlying such option. The remaining ADSs will vest on the one year anniversary of the First Vesting Date, subject to the Reporting Person's continued service at such time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 4, 2022, the Reporting Person was granted an option to purchase 350,000 ADSs, for which vesting was subject to the satisfaction of certain performance criteria. The performance criteria were met on June 5, 2023 (the \"First Vesting Date\"), resulting in the vesting of 50% of the ADSs underlying such option. The remaining ADSs will vest on the one year anniversary of the First Vesting Date, subject to the Reporting Person's continued service at such time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":350000,"derivative":{"exercise_price":4.69,"expiration_date":"2032-08-04","underlying":"ADSs","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001104659-23-068234","document":"tm2317881-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465923068234/tm2317881-1_4seq1.xml","form_type":"4"}},{"id":2251976,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"ADSs","published_at":"2022-05-31T07:13:23.000Z","date":"2022-05-27","kind":"purchase","acquired":true,"shares":50000,"price":2.05,"value":102500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":149100,"source":{"system":"sec-edgar","filing":"0001104659-22-066221","document":"tm2217241-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465922066221/tm2217241-1_4seq1.xml","form_type":"4"}},{"id":2265491,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2022-05-18T16:33:45.000Z","date":"2022-05-18","kind":"exercise","acquired":false,"shares":12133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the \"Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12133},"source":{"system":"sec-edgar","filing":"0001104659-22-062476","document":"tm2215330-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465922062476/tm2215330-1_4seq1.xml","form_type":"4"}},{"id":2265490,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-18T16:33:45.000Z","date":"2022-05-18","kind":"exercise","acquired":true,"shares":12133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the \"Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock."}],"balance_after":12133,"source":{"system":"sec-edgar","filing":"0001104659-22-062476","document":"tm2215330-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465922062476/tm2215330-1_4seq1.xml","form_type":"4"}},{"id":2314120,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2022-03-30T21:43:51.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":85900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in full on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in full on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice."}],"balance_after":85900,"derivative":{"underlying":"Common Stock","underlying_shares":85900},"source":{"system":"sec-edgar","filing":"0001104659-22-040408","document":"tm2210715-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465922040408/tm2210715-2_4seq1.xml","form_type":"4"}},{"id":2479576,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-09T18:45:15.000Z","date":"2021-12-07","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options become exercisable as to 77,500 ADSs on each of the first four anniversaries after the 12/07/2021 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":310000,"derivative":{"exercise_price":8.2,"expiration_date":"2031-12-07","underlying":"ADSs","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001179110-21-010795","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000117911021010795/edgar.xml","form_type":"4"}},{"id":2702920,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-05-20T17:02:33.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":36400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The option and restricted stock unit grants were approved by the issuer's board of directors on May 18, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vest in full on May 18, 2022, the first anniversary of the grant date.  Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vest in full on May 18, 2022, the first anniversary of the grant date.  Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice."}],"balance_after":36400,"derivative":{"underlying":"Common Stock","underlying_shares":36400},"source":{"system":"sec-edgar","filing":"0001104659-21-069972","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465921069972/a4.xml","form_type":"4"}},{"id":2702919,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-05-20T17:02:33.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":72750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The option and restricted stock unit grants were approved by the issuer's board of directors on May 18, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest in full on May 18, 2022, the first anniversary of the grant date, so long as the director continues to serve on the board of directors of the issuer."}],"balance_after":72750,"derivative":{"exercise_price":1.24,"expiration_date":"2031-05-18","underlying":"Common Stock","underlying_shares":72750},"source":{"system":"sec-edgar","filing":"0001104659-21-069972","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465921069972/a4.xml","form_type":"4"}},{"id":2952373,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-09T16:08:08.000Z","date":"2020-12-08","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options become exercisable as to 125,000 ADSs on each of the first four anniversaries after the 12/08/2020 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":500000,"derivative":{"exercise_price":6.79,"expiration_date":"2030-12-08","underlying":"ADSs","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001179110-20-011791","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000117911020011791/edgar.xml","form_type":"4"}},{"id":3059100,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"ADSs","published_at":"2020-08-13T19:39:37.000Z","date":"2020-08-12","kind":"purchase","acquired":true,"shares":13000,"price":7.7812,"value":101155.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.69 to $7.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary)."}],"balance_after":99100,"source":{"system":"sec-edgar","filing":"0001179110-20-009023","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/edgar.xml","form_type":"4"}},{"id":3196217,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"Divis Gregory J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-03-24T21:30:25.000Z","date":"2020-03-20","kind":"grant","acquired":true,"shares":26533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Stock Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the issuer's board of directors on March 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the director remains employed by the issuer."}],"balance_after":26533,"derivative":{"exercise_price":0.45,"expiration_date":"2030-03-20","underlying":"Common Stock","underlying_shares":26533},"source":{"system":"sec-edgar","filing":"0001104659-20-037929","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465920037929/a4.xml","form_type":"4"}},{"id":3366653,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"ADSs","published_at":"2019-11-19T17:00:54.000Z","date":"2019-11-15","kind":"purchase","acquired":true,"shares":19000,"price":5.13,"value":97470.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary)."}],"balance_after":86100,"source":{"system":"sec-edgar","filing":"0001567619-19-021885","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/doc1.xml","form_type":"4"}},{"id":3455196,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-07-26T16:52:00.000Z","date":"2019-07-24","kind":"grant","acquired":true,"shares":121573,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the issuer's 2014 Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019.  Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in equal monthly installments beginning on July 24, 2019, with one month of options, or 3,377 options, vested as of the grant date based on the reporting person's number of years of service on the issuer's board of directors, such that the grant is vested in full on the 3-year anniversary of the grant date."}],"balance_after":121573,"derivative":{"exercise_price":1.73,"expiration_date":"2022-07-24","underlying":"Common Stock","underlying_shares":121573},"source":{"system":"sec-edgar","filing":"0001104659-19-042088","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465919042088/a4.xml","form_type":"4"}},{"id":3505375,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-03T17:39:19.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Options become exercisable as to 100,000 ADSs on each of the first four anniversaries after the 5/30/2019 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":400000,"derivative":{"exercise_price":1.71,"expiration_date":"2029-05-30","underlying":"ADSs","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001567619-19-012607","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000156761919012607/doc1.xml","form_type":"4"}},{"id":3602866,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-11T19:04:53.000Z","date":"2019-03-07","kind":"grant","acquired":true,"shares":100000,"price":1.85,"value":185000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.85,"expiration_date":"2029-03-07","underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-19-006609","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000156761919006609/doc1.xml","form_type":"4"}},{"id":3602865,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"ADSs","published_at":"2019-03-11T19:04:53.000Z","date":"2019-03-07","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary)."}],"balance_after":67100,"source":{"system":"sec-edgar","filing":"0001567619-19-006609","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000156761919006609/doc1.xml","form_type":"4"}},{"id":3867955,"issuer":{"id":8387,"kind":"organization","name":"Jaguar Health, Inc."},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-07-13T17:34:16.000Z","date":"2018-07-11","kind":"grant","acquired":true,"shares":104860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's 2014 Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F2","text":"The option grant was approved by the Issuer's board of directors on July 11, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in equal monthly installments, beginning on July 11, 2018, such that it is vested in full on the 3-year anniversary of the grant date."}],"balance_after":104860,"derivative":{"exercise_price":1.36,"expiration_date":"2028-07-11","underlying":"Common Stock","underlying_shares":104860},"source":{"system":"sec-edgar","filing":"0001104659-18-045068","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410677/000110465918045068/a4.xml","form_type":"4"}},{"id":3882558,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"ADSs","published_at":"2018-06-27T19:00:11.000Z","date":"2018-06-26","kind":"purchase","acquired":true,"shares":16000,"price":6,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant)."}],"balance_after":49100,"source":{"system":"sec-edgar","filing":"0001140361-18-030198","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036118030198/doc1.xml","form_type":"4"}},{"id":3984276,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-23T16:56:51.000Z","date":"2018-03-22","kind":"grant","acquired":true,"shares":50000,"price":7.06,"value":353000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 3/22/2018 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":50000,"derivative":{"exercise_price":7.06,"expiration_date":"2028-03-22","underlying":"ADSs","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-18-014819","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036118014819/doc1.xml","form_type":"4"}},{"id":4132238,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2017-12-14T16:15:25.000Z","date":"2017-12-12","kind":"grant","acquired":true,"shares":100000,"price":8.95,"value":895000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."}],"balance_after":100000,"derivative":{"exercise_price":8.95,"expiration_date":"2027-12-12","underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001140361-17-046232","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117046232/doc1.xml","form_type":"4"}},{"id":4132237,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"ADSs","published_at":"2017-12-14T16:15:25.000Z","date":"2017-12-12","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant)."}],"balance_after":33100,"source":{"system":"sec-edgar","filing":"0001140361-17-046232","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117046232/doc1.xml","form_type":"4"}},{"id":4209679,"issuer":{"id":65991,"kind":"organization","name":"AVADEL PHARMACEUTICALS PLC","symbol":"AVDL"},"owners":[{"id":66773,"kind":"person","name":"Divis Gregory J","position":1,"cik":"0001410677","reported_name":"DIVIS GREG J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"ADSs","published_at":"2017-09-14T17:03:05.000Z","date":"2017-09-12","kind":"purchase","acquired":true,"shares":10600,"price":9.317,"value":98760.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The issuer's \"ADSs\" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.14 to $9.85, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2)."}],"balance_after":10600,"source":{"system":"sec-edgar","filing":"0001140361-17-035544","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1012477/000114036117035544/doc1.xml","form_type":"4"}}]}